Rezolute
Open
$4.00
Prev. Close
$4.00
High
$4.03
Low
$3.98
Market Snapshot
$382.79M
-4.7
-1.22
71
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Recently from Cashu
Rezolute Engages FDA on Phase 3 sunRIZE Trial for Ersodetug in Hyperinsulinism Treatment
Rezolute Engages with FDA on Phase 3 Trial for Ersodetug in Treating Congenital Hyperinsulinism Rezolute marks a pivotal moment in its ongoing mission to develop novel treatments for patients sufferin…
Rezolute Advances Phase 3 Trial for Congenital Hyperinsulinism Drug with FDA Collaboration
Rezolute Engages FDA on Phase 3 Trial for Congenital Hyperinsulinism Drug In a significant development for the biotechnology firm Rezolute, the company shares crucial insights from its recent meeting…
Rezolute Faces Major Setback and Legal Scrutiny After Disappointing Trial Results
Severe Clinical Setback for Rezolute Raises Legal Concerns Rezolute, Inc. confronts a significant challenge as recent developments relating to its leading drug candidate pose a threat to its future pr…
Rezolute's Stock Plummets 90% After Failed Hypoglycemia Trial Raises Investor Concerns
Rezolute Faces Scrutiny After Failed Clinical Trial for Hypoglycemia Treatment Rezolute, Inc. is currently grappling with significant fallout following the disappointing results of its Phase 3 clinica…